Search
Close
Search
Advanced Search
Search Menu
AI Discovery Assistant

Erratum to:

Risk of thrombocytopenia with glycoprotein IIb/IIIa inhibitors across drugs and patient populations: a meta-analysis of 29 large placebo-controlled randomized trials [Eur Heart J Cardiovasc Pharmacother (2015) 1(2):97–106]

What is the need for another new journal? [Eur Heart J Cardiovasc Pharmacother (2015) 1(2):74–75]

How European Society of Cardiology guidelines are made [Eur Heart J Cardiovasc Pharmacother (2015) 1(2):82]

Simple decision-making between a vitamin K antagonist and a non-vitamin K antagonist oral anticoagulant: using the SAMe-TT2R2 score [Eur Heart J Cardiovasc Pharmacother (2015) 1(3):150–152]

Medical management: the dark side of acute coronary syndromes [Eur Heart J Cardiovasc Pharmacother (2015) 1(3):179–181]

Closing the information gap between clinical and postmarketing trials: the case of dabigatran [Eur Heart J Cardiovasc Pharmacother (2015) 1(3):153–156]

Exploring the potential of low-dose sulfasalazine in stable coronary artery disease patients: randomized, double-blind, placebo-controlled study [Eur Heart J Cardiovasc Pharmacother (2015) 1(4):214–216]

Meta-analysis of admission hyperglycaemia in acute myocardial infarction patients treated with primary angioplasty: a cause or a marker of mortality? [Eur Heart J Cardiovasc Pharmacother (2015) 1(4):220–228]

Cardiovascular pharmacology: a look back and a glimpse into the future [Eur Heart J Cardiovasc Pharmacother (2015) 1(1):7–9]

Stroke prevention in atrial fibrillation: changing concepts [Eur Heart J Cardiovasc Pharmacother (2015) 1(2):76–79]

Renal denervation: back to reality, finally! [Eur Heart J Cardiovasc Pharmacother (2015) 1(1):57]

Editorial Comment for the “Risk of Thrombocytopenia with Glycoprotein IIb/IIIa Inhibitors across Drugs and Patient Populations: a Meta-Analysis of 29 Large Placebo-Controlled Randomized Trials”. Thrombocytopenia as an important complication with the use of antithrombotic agents [Eur Heart J Cardiovasc Pharmacother (2015) 1(1):29–30]

Back to the future: the crucial role of clinical registries in the era of randomized controlled trials for identifying the optimal medical therapy of heart failure [Eur Heart J Cardiovasc Pharmacother (2015) 1(1):37–38]

Editorial comment on ‘A novel approach indirectly comparing benefit: risk across oral antithrombotic therapies in patients with atrial fibrillation’. Are the evidences of current dose-adjusted anticoagulation with warfarin stroke prevention for patients with atrial fibrillation sufficient enough to compare with newly developed non-vitamin K oral anticoagulants? [Eur Heart J Cardiovasc Pharmacother (2015) 1(2):83–85]

Cardiorenal protection during chronic renin–angiotensin–aldosterone system suppression: evidences and caveats [Eur Heart J Cardiovasc Pharmacother (2015) 1(2):126–131]

Non-steroidal anti-inflammatory drugs and incident atrial fibrillation [Eur Heart J Cardiovasc Pharmacother (2015) 1(2):115–116]

Did referral patterns for coronary angiography change in Europe? What can we learn from Denmark? [Eur Heart J Cardiovasc Pharmacother (2015) 1(3):166–167]

Synergistic effects of cardiac resynchronization therapy and drug up-titration in heart failure: is this enough? [Eur Heart J Cardiovasc Pharmacother (2015) 1(3):189–190]

Glycemic control and acute coronary syndrome: the debate continues [Eur Heart J Cardiovasc Pharmacother (2015) 1(4):229–231]

Potassium levels in acute myocardial infarction: definitely worth paying attention to [Eur Heart J Cardiovasc Pharmacother (2015) 1(4):252–253]

The Publisher regrets that the above papers were published without a conflict of interest statement. This has now been amended online by post-production correction.

Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2016. For permissions please email: [email protected]
Issue Section:
Erratum
Download all slides